Binnopharm Group Presents New Opportunities for Treating Endometriosis and Hormone-Dependent Diseases

The program focuses on modern approaches to the treatment of endometriosis and menstrual cycle disorders, as well as a presentation of the capabilities of new drugs in the Binnopharm Group gynecological line in the treatment of hormone-dependent conditions.

The scientific block started with a master class led by Honored Doctor of the Russian Federation, Professor, Doctor of Medical Sciences Vitaly Borisovich Tskhai and his team. The participants were shown the clinical aspects of the interdisciplinary approach to the treatment of endometriosis: from diagnostics to surgical interventions and drug therapy. Professor Tskhai noted that endometriosis remains a socially significant disease with a chronic course, and emphasized the importance of the emergence of an affordable drug, micronized dienogest, which expands the possibilities of drug treatment for patients in Russia.

The central event of the day was the symposium "Hormonal Detective. The Investigation is Led by Experts", moderated by Academician of the Russian Academy of Sciences, Professor, Doctor of Medical Sciences Viktor Evseevich Radzinsky. The discussion was attended by key experts in the country in the field of endocrine gynecology: Professor of the Russian Academy of Sciences, Doctor of Medical Sciences, Honored Scientist of the Russian Federation Maria Igorevna Yarmolinskaya and leading researcher, PhD Ekaterina Viktorovna Sheremetyeva. In the format of a "clinical investigation", they discussed strategies for treating menstrual irregularities, endometriosis and additional benefits of hormonal contraception in women with special needs. A new portfolio of Binnopharm Group drugs was presented at the symposium, opening up additional opportunities for doctors to treat hormone-dependent diseases.

The final focus of the program was the plenary report of Professor, Doctor of Medical Sciences, Honored Scientist of the Russian Federation Marina Borisovna Khamoshina. She presented an overview of the modern role of dydrogesterone in outpatient practice, based on the latest clinical recommendations, and emphasized the importance of the emergence of domestic analogues of original drugs to maintain continuity of therapy and increase the availability of treatment.

Natalia Oliferuk, Head of the Medical Department at Binnopharm Group: “The events attracted great interest from the audience and demonstrated a high level of expert dialogue. We were attended by specialists from 80 regions of Russia and doctors from 13 countries. With the launch of the gynecological line, Binnopharm Group faced an important task – to inform doctors about available therapy. Our priority is not just to be a manufacturer of high-quality drugs, but also to conduct educational activities, discuss modern methods of treating socially significant diseases with the professional community and interact in an open dialogue with doctors who solve the problems of thousands of women.”